ПОРАЖЕНИЕ ЛЕГКИХ ПРИ СИСТЕМНОЙ КРАСНОЙ ВОЛЧАНКЕ: ХОРОШО ИЗВЕСТНЫЕ ФАКТЫ И НЕРЕШЕННЫЕ ВОПРОСЫ
Аннотация
В обзоре представлены данные литературы о клинических проявлениях, методах диагностики, гистологических особенностях, прогнозе и ответе на терапию различных поражений легких при системной красной волчанке (СКВ). Приведены собственные данные о спектре легочной патологии у больных СКВ и описание клинического случая.
Об авторах
Н. Г. Клюквина
Первый Московский государственный медицинский университет имени И.М. Сеченова
Россия
Россия
Наталия Геннадьевна Клюквина - кафедра ревматологии Института профессионального образования.
1119991 Москва, ул. Трубецкая, 8
Е. А. Асеева
Научноисследовательский институт ревматологии имени В.А. Насоновой
Россия
2115522 Москва, Каширское шоссе, 34А
Россия
2115522 Москва, Каширское шоссе, 34А
Н. О. Никонорова
Научноисследовательский институт ревматологии имени В.А. Насоновой
Россия
2115522 Москва, Каширское шоссе, 34А
Россия
2115522 Москва, Каширское шоссе, 34А
Список литературы
1. Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: A comparison of worldwide disease burden. Lupus. 2006;15:308-18. doi: 10.1191/0961203306lu2305xx
2. Gaubitz M. Epidemiology of connective tissue disorders. Rheumatology. 2006;45S:iii3-4. doi: 10.1093/rheumatology/kel282
3. Насонов ЕЛ, редактор. Ревматология. Клинические рекомендации. 2-е изд. Москва: ГЭОТАР-Медиа; 2010 [Nasonov EL, editor. Revmatologiya. Klinicheskie rekomendatsii [Rheumatology. Clinical guidelines]. 2nd ed. Moscow: GEOTAR Media; 2010].
4. Клюквина НГ, Насонов ЕЛ. Особенности клинических и лабораторных проявлений системной красной волчанки. Современная ревматология. 2012;6(4):40-8 [Klyukvina NG, Nasonov EL. The clinical and laboratory manifestations of systemic lupus erythematosus. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2012;6(4):40-8 (In Russ.)]. doi: 10.14412/1996-7012-2012-761
5. Gutsche M, Rosen GD, Swigris JJ. Connective tissue diseaseassociated interstitial lung disease: A review. Curr Respir Care Rep. 2012;1:224-32. doi: 10.1007/s13665-012-0028-7
6. Todd DJ, Costenbader KH. Dyspnoea in a young woman with active systemic lupus erythematosus. Lupus. 2009;18:777-84. doi: 10.1177/0961203309104860
7. Pego-Reigosa JM, Medeiros DA, Isenberg DA. Respiratory manifestations of systemic lupus erythematosus: old and new concepts. Best Pract Res Clin Rheumatol. 2009;23:469-80. doi: 10.1016/j.berh.2009.01.002
8. Haupt HM, Moore GW, Hutchins GM. The lung in systemic lupus erythematosus. Analysis of the pathologic changes in 120 patients. Am J Med. 1981;71:791-8. doi: 10.1016/0002-9343(81)90366-1
9. Quadrelli SA, Alvarez C, Arce SC, et al. Pulmonary involvement of systemic lupus erythematosus: analysis of 90 necropsies. Lupus. 2009;18:1053-60. doi: 10.1177/0961203309106601
10. Ghafoor Gari AG, Telmesani A, Alwithenani R. Pulmonary manifestations of systemic lupus erythematosus. Available from: www.intechopen.com
11. Swigris JJ, Fischer A, Gilles J, et al. Pulmonary and thrombotic manifestations of systemic lupus erythematosus. Chest. 2008;133:271-80. doi: 10.1378/chest.07-0079
12. Kamen DL, Strange C. Pulmonary manifestations of systemic lupus erythematosus. Clin Chest Med. 2010;31:479-88. doi: 10.1016/j.ccm.2010.05.001
13. Carette S, Macher AM, Nussbaum A, Plotz PH. Severe, acute pulmonary disease in patients with systemic lupus erythematosus: ten years of experience at the National Institutes of Health. Semin Arthritis Rheum. 1984;14:52-9. doi: 10.1016/0049-0172(84)90009-X
14. Santos-Ocampo AS, Mandell BF, Fessler BJ. Alveolar hemorrhage in systemic lupus erythematosus: presentation and management. Chest. 2000;118:1083-90.
15. Zamora MR, Warner ML, Tuder R, Schwarz MI. Diffuse alveolar hemorrhage and systemic lupus erythematosus. Clinical presentation, histology, survival, and outcome. Medicine (Baltimore). 1997;76:192-202. doi: 10.1097/00005792-199705000-00005
16. Pottier V, Pierrot M, Subra JF, et al. Successful rituximab therapy in a lupus patient with diffuse alveolar haemorrhage. Lupus. 2011;20:656-9. doi: 10.1177/0961203310386276
17. Tansey D, Wells AU, Colby TV, et al. Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis. Histopathology. 2004;44:585-96. doi: 10.1111/j.1365-2559.2004.01896.x
18. Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society Statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonitis. Am J Respir Crit Care Med. 2013;138(6):733-48. doi: 10.1164/rccm.201308-1483ST
19. Schattner A, Aviel-Ronen S, Mark EJ. Accelerated usual interstitial pneumonitis, anti-DNA antibodies and hypocomplementemia. J Intern Med. 2003;254:193-6. doi: 10.1046/j.1365-2796.2003.01144.x
20. Filipek MS, Thompson ME, Wang P, et al. Lymphocytic interstitial pneumonitis in a patient with systemic lupus erythematosus: radiographic and high-resolution CT findings. J Thorac Imaging. 2004;19:200-3. doi: 10.1097/01.rti.0000099464.94973.51
21. Bodolay E, Szekanecz Z, Devenyi K, et al. Evaluation of interstitial lung disease in mixed connective tissue disease (MCTD). Rheumatology (Oxford). 2005; 44:656-61. doi: 10.1093/rheumatology/keh575
22. Chen LJ, Chang HC, Lu LY, et al. Prolonged survival after single lung transplantation for pulmonary hypertension secondary to systemic lupus erythematosus. J Chin Med Assoc. 2004;67:248-51.
23. Kamel SR, Omar GM, Darwish AF, et al. Asymptomatic pulmonary hypertension in systemic lupus erythematosus. Arthr Musculoskel Dis. 2011;4:77-86. doi: 10.4137/CMAMD.S7667
24. Cummings P. Primary pulmonary hypertension and SLE. N Engl J Med. 1973;288:1078-9. doi: 10.1056/NEJM197305172882018
25. Lian F, Chen D, Wang Y, et al. Clinical features and independent predictors of pulmonary arterial hypertension in systemic lupus erythematosus. Rheumatol Int. 2011;32(6):1727-31. doi: 10.1007/s00296-011-1880-4
26. Asherson RA, Higenbottam TW, Dinh Xuan AT, et al. Pulmonary hypertension in a lupus clinic. Experience with twenty-four patients. J Rheumatol. 1990;17(10):1292-8.
27. Robbins IM, Gaine SP, Schilz R, et al. Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus. Chest. 2000;117:14-8. doi: 10.1378/chest.117.1.14
28. Fois E, Guern VL, Dupuy A, et al. Noninvasive assessment of systolic pulmonary artery pressure in systemic lupus erythematosus: retrospective analysis of 93 patients. Clin Exper Rheumatol. 2010;28:836-41.
29. Чазова ЕИ, Авдеев СН, Царева НА и др. от имени рабочей группы по разработке и подготовке текста Российских рекомендаций по диагностике и лечению ЛГ. Клинические рекомендации по лечению легочной гипертонии. Терапевтический архив. 2014;(9):1-20 [Chazova IE, Avdeev SN, Tsareva NA, et al., on behalf of a Working Group on the Elaboration and Preparation of the Text of Russian Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. Clinical guidelines for the diagnosis and treatment of pulmonary hypertension. Terapevticheskiy Arkhiv. 2014;(9):1-20 (In Russ.)].
30. Pope J. An update in pulmonary hypertension in systemic lupus erythematosus – do we need to know about it? Lupus. 2008;17:274-7. doi: 10.1177/0961203307087188
31. Abramson SB, Dobro J, Eberle MA, et al. Acute reversible hypoxemia in systemic lupus erythematosus. Ann Intern Med. 1991;114:941-7. doi: 10.7326/0003-4819-114-11-941
32. Martinez-Taboada VM. Acute reversible hypoxemia in systemic lupus erythematosus: a new syndrome or an index of disease activity? Lupus. 1995;4:259-62. doi: 10.1177/096120339500400405
33. Naval E, Domingo Ch, Gratacos J, et al. Shrinking lung syndrome:a pulmonary manifestation of systemic lupus erythematosus diurnal findings and nocturnal events. J Appl Res. 2004;4(2):329-35.
34. Toya SP, Tzelepis GE. Association of the shrinking lung syndrome in systemic lupus erythematosus with pleurisy: a systematic review. Semin Arthritis Rheum. 2009;39:30-7. doi: 10.1016/j.semarthrit.2008.04.003
35. Bankier AA, Kiener HP, Wiesmayr MN, et al. Discrete lung involvement in systemic lupus erythematosus: CT assessment. Radiology. 1995;196:835-40. doi: 10.1148/radiology.196.3.7644652
36. Mateda R, Isowa N, Miura H, Tokuyasi H. Systemic lupus erythematosus with multiple lung cysts. Interactive CardioVasc Thorac Surg. 2009;8:701-2. doi: 10.1510/icvts.2008.200055
37. Wiedemann HP, Matthay RA. Pulmonary manifestations of the collagen vascular diseases. Clin Chest Med. 1989;10:677-722.
38. Wilhelm M, van Why SK. Pneumothoraces complicating systemic lupus erythematosus with nephritis. Pediatr Nephrol. 2002;17:261-3. doi: 10.1007/s00467-001-0803-0
39. Calderaro DC, Ferreira GA. Presentation and prognosis of shrinking lung syndrome in systemic lupus erythematosus: report of four cases. Rheumatol Int. 2012;32(5):1391-6. doi: 10.1007/s00296-011-1863-5
40. Wells AU, du Bois RM. Bronchiolitis in association with connective tissue disorders. Clin Chest Med. 1993;14:655-66.
41. Doria A, Canoya M, Tonon M, et al. Infections as triggers and complications of systemic lupus erythematosus. Autoimmun Rev. 2008;8:24-8. doi: 10.1016/j.autrev.2008.07.019
42. Tikly M, Navarra SV. Lupus in the developing world – is it any different? Best Pract Res Clin Rheumatol. 2008;22:643-55. doi: 10.1016/j.berh.2008.05.003
43. Goldblatt F, Chambers S, Rahman A, Isenberg DA. Serious infections in British patients with systemic lupus erythematosus: hospitalizations and mortality. Lupus. 2009;18(8):682-9. doi: 10.1177/0961203308101019
44. Barber C, Gold WL, Fortin PR. Infections in the lupus patient: perspectives on prevention. Curr Opin Rheumatol. 2011;23(4):358-65. doi: 10.1097/BOR.0b013e3283476cd8
45. Bosch X, Guilabert A, Pallares L, et al. Infections in systemic lupus erythematosus: a prospective and controlled study of 110 patients. Lupus. 2006;15(9):584-9. doi: 10.1177/0961203306071919
46. Petri M. Infection in systemic lupus erythematosus. Rheum Dis Clin North Am. 2008;24(2):423-56.
47. Li J, Huang XM, Fang WG, Zeng XJ. Pneumocystis carinii pneumonia in patients with connective tissue disease. J Clin Rheumatol. 2006;12:114-7. doi: 10.1097/01.rhu.0000221794.24431.36
48. Lim SW, Gillis D, Smith W, et al. Rituximab use in systemic lupus erythematosus pneumonitis and a review of current reports. Intern Med J. 2006;36:260-2. doi: 10.1111/j.1445-5994.2006.01055.x
49. WHO Report 2009 Global Tuberculosis Control. Country Profile – Brazil, pp. 89-92. Available from: http://apps.who.int/globalatlas/predefineReports/TB/PDF_Fil es/bra.pdf (accessed February 2010).
50. Hernandez-Cruz B, Sifuentes-Osornio J, Ponce-de-Leon RS, et al. Mycobacterium tuberculosis infection in patients with systemic rheumatic diseases. A case-series. Clin Exp Rheumatol. 1999;17:289-96.
51. Pasoto SG, Borba EF, Bonfa E, Shinjo SK. Lupus pleuritis: a relevant risk factor for pulmonary tuberculosis. Lupus. 2010;19:1385-90. doi: 10.1177/0961203310375269
52. Yun JE, Lee SW, Kim TH, et al. The incidence and clinical characteristics of Mycobacterium tuberculosis infection among systemic lupus erythematosus and rheumatoid arthritis patients in Korea. Clin Exp Rheumatol. 2002;20:127-32.
53. Tam LS, Li EK, Wong SM, Szeto CC. Risk factors and clinical features for tuberculosis among patients with systemic lupus erythematosus in Hong Kong. Scand J Rheumatol. 2002;31:296-300. doi: 10.1080/030097402760375205
54. Sayarlioglu M, Inanc M, Kamali S, et al. Tuberculosis in Turkish patients with systemic lupus erythematosus: increased frequency of extrapulmonary localization. Lupus. 2004;13:274-8. doi: 10.1191/0961203303lu529xx
55. Kim HA, Yoo CD, Baek HJ, et al. Mycobacterium tuberculosis infection in a corticosteroid-treated rheumatic disease patient population. Clin Exp Rheumatol. 1998;16:9-13.
56. Erdozain J-G, Ruiz-Irastorza G, Egurbide M-V, et al. High risk of tuberculosis in systemic lupus erythematosus? Lupus. 2006;15:232-5. doi: 10.1191/0961203306lu2289xx
57. Hou CL, Tsai YC, Chen LC, Huang JL. Tuberculosis infection in patients with systemic lupus erythematosus: pulmonary and extrapulmonary infection compared. Clin Rheumatol. 2008;27:557-63. doi: 10.1007/s10067-007-0741-8
58. Jee SH, Golub JE, Jo J, et al. Smoking and risk of tuberculosis incidence, mortality, and recurrence in South Korean men and women. Am J Epidemiol. 2009;170:1478-85. doi: 10.1093/aje/kwp308
59. Chang KC, Leung CC, Tam CM. Tuberculosis risk factors in a silicotic cohort in Hong Kong. Int J Tuberc Lung Dis. 2001;5:177-84.
60. Lee E, Holzman RS. Evolution and current use of the tuberculin test. Clin Infect Dis. 2002;34:365-70. doi: 10.1086/338149
61. Fischer A, du Bois RM. Lung. Chapter 45. In: Lahita RG, editor. Systemic Lupus erythematosus. 5th ed. London: Elsevier; 2011. P. 850-64.
62. Bertoli AM, Vila LM, Apte M, et al. Systemic lupus erythematosus in a multiethnic U.S. cohort LUMINA XLVIII: Factors predictive of pulmonary damage. Lupus 2007;16:410-7. doi: 10.1177/0961203307079042
63. Memet B, Ginzler EM. Pulmonary manifestations of systemic lupus erythematosus. Semin Respir Crit Care Med. 2007;28:441-50. doi: 10.1055/s-2007-985665
64. Andonopoulos AP, Constantopoulos SH, Galanopoulou V, et al. Pulmonary function of non-smoking patients with systemic lupus erythematosus. Chest. 1988;94:312-5. doi: 10.1378/chest.94.2.312
65. Fenlon HM, Doran M, Sant SM, Breatnach E. High-resolution chest CT in systemic lupus erythematosus. Am J Roentgenol. 1996;166:301-7. doi: 10.2214/ajr.166.2.8553934
66. Cottin V. Interstitial lung disease: are we missing formes frustes of connective tissue disease? Eur Respir J. 2006;28:893-6. doi: 10.1183/09031936.00101506
67. Fischer A, Brown KK, Frankel SK. Treatment of connective tissue disease related interstitial lung disease. Clin Pulm Med. 2016;16:74-80. doi: 10.1097/CPM.0b013e31819b5400
68. Алекперов РТ, Черемухина ЕО, Ананьева ЛП и др. Одностороннее поражение легких при системной склеродермии (описание случая). Научно-практическая ревматология. 2014;52(4):458-63 [Alekperov RT, Cheremukhina EO, Ananyeva LP, et al. Unilateral lung injury in scleroderma systematica: a case report. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(4):458-63 (In Russ.)]. doi: 10.14412/1995-4484-2014-458-463
69. Morgan C, Knight C, Lunt M, et al. Preductors of end stage lung disease in a cohort of patients with scleroderma. Ann Rheum Dis. 2003;62:146-50. doi: 10.1136/ard.62.2.146
70. Castillo-Martinez D. Levels of uric acid may predict future development of pulmonary hypertension in systemic lupus erythematosus: a seven-year follow-up study. Lupus. 2015 Aug 24. pii: 0961203315600539.
71. Бестаев ДВ, Каратеев ДЕ, Насонов ЕЛ. Интерстициальное поражение легких как внесуставное проявление ревматоидного артрита (лекция). Научно-практическая ревматология. 2013;51(3):290-5 [Bestaev DV, Karateev DE, Nasonov EL. Interstitial lung disease as an extra-articular manifestation of rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013;51(3):290-5 (In Russ.)]. doi: 10.14412/1995-4484-2013-1504
72. Galie N. 2015 ECS/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. The Joint Task Force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology and the European Respiratory Society. Eur Heart J. 2015 Aug29; pii:ehv317.
73. Fisher A, West SG, Swigris JJ, et al. Connective tissue diseaseassociated interstitial lung disease: a call for clarification. Chest. 2010;138(2):251-6. doi: 10.1378/chest.10-0194
74. Vij R, Noth I, Strek ME. Autoimmune-featured interstitial lung disease: a distinct entity. Chest. 2011;140(5):1292-9. doi: 10.1378/chest.10-2662
Для цитирования:
Клюквина Н.Г., Асеева Е.А., Никонорова Н.О. ПОРАЖЕНИЕ ЛЕГКИХ ПРИ СИСТЕМНОЙ КРАСНОЙ ВОЛЧАНКЕ: ХОРОШО ИЗВЕСТНЫЕ ФАКТЫ И НЕРЕШЕННЫЕ ВОПРОСЫ. Научно-практическая ревматология. 2016;54(5):578-589. https://doi.org/10.14412/1995-4484-2016-578-589
For citation:
Klyukvina N.G., Aseeva E.A., Nikonorova N.O. LUNG INVOLVEMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS: WELL-KNOWN FACTS AND UNSOLVED ISSUES. Rheumatology Science and Practice. 2016;54(5):578-589. (In Russ.) https://doi.org/10.14412/1995-4484-2016-578-589
Просмотров: 1018
Послать статью по эл. почте 
